KT-579 Significantly Decreases IgG, Complement 3 (C3) and Renal
Disease Progression
                                                     Assessment of Terminal Kidney Collected from Surviving MRL/lpr Mice at Week 19
                                                15
                                                           IgG                                                                    10
                                                                                                                                                     C3                                                   6
                                                                                                                                                                                                              Total Kidney Lesions




       % IgG+ Area of Renal Cortex Area + SEM                                             % C3+ Area of Renal Cortex Area + SEM
                                                                                                                                                                        Total Kidney Lesion Score + SEM
                                                                                                                                  8                                                                                                                   Vehicle
                                                                                                                                                                                                                                                      KT-579 50 mg/kg
                                                10                                                                                                                                                        4
                                                                                                                                  6                                                                                                                   KT-579 200 mg/kg
                                                                                                                                                                                                                                                      Afimetoran
                                                                                                                                                                                                                                                      Deucravacitinib
                                                                                                                                  4
                                                5                                                                                                                                                         2
                                                                                                                                                                                                                *                                     Cyclophosphamide
                                                                                                                                                                                                                                                      Anti-IFNAR
                                                                                                                                  2                   *                                                                      *
                                                                                                                                                                                                                    *
                                                            *                                                                                *   *
                                                                        *                                                                                 *
                                                0                                                                                 0                                                                       0

                                                                         *p≤0.01                                                                              *p≤0.05                                                            *p≤0.05 vs vehicle

                                                      Vehicle IgG                                                                      KT-579 IgG                       Vehicle C3                                                            KT-579 C3

      IgG                                                                          IgG                                                                        Complement 3                                                   Complement 3
      DAPI                                                                         DAPI                                                                        DAPI                                                          DAPI




                                                     Representative images (10x) of IgG and C3 staining in vehicle vs KT-579 treated MRL/lpr kidney glomerular structures


Clear reduction in IgG/complement glomeruli staining indicating reduced kidney disease involvement in SLE MRL/lpr mouse
                              model with IRF5 degrader as compared to standard of care
                                                                                                                                                                                                                                                                         46
